Author:
Oxford J. S.,Catchpole A.,Mann A.,Bell A.,Noulin N.,Gill D.,Oxford J. R.,Gilbert A.,Balasingam Shobana
Publisher
Springer Berlin Heidelberg
Reference103 articles.
1. Akst J (08/10/2020) A challenge trial for COVID-19 would not be the first of its kind|The scientist magazine® retrieved from a challenge trial for COVID-19 would not be the first of its kind|The scientist magazine® (the-scientist.com) (accessed 23 May 2021)
2. Avila PC, Abisheganaden JA, Wong H, Liu J, Yagi S, Schnurr D, Kishiyama JL, Boushey HA (2000) Effects of allergic inflammation of the nasal mucosa on the severity of rhinovirus 16 cold. J Allergy Clin Immunol 105(5):923–932
3. Balasingam S, Wilder-Smith A (2016) Randomised controlled trials for influenza drugs and vaccines: a review of controlled human infections studies. Int J Infect Dis 49:18–29
4. Balasingam S, Horby P, Wilder-Smith A (2014) The potential for a controlled human infection platform in Singapore. Singapore Med J 55(9):456–461
5. Bardin PG, Fraenkel DJ, Sanderson G, van Schalkwyk EM, Holgate ST, Johnston SL (2000) Peak expiratory flow changes during experimental rhinovirus infection. Eur Respir J 16:980–985